Development of CAR-T cells for long-term eradication and surveillance of HIV-1 reservoir
Development of CAR-T cells for long-term eradication and surveillance of HIV-1 reservoir
复制标题
开发用于长期根除和监测 HIV-1 病毒库的 CAR-T 细胞。
DOI：
10.1016/j.coviro.2019.04.004
复制
发表时间：
2019-10-01
影响因子：
5.9
通讯作者：
Zhang, Hui
中科院分区：
文献类型：
--
作者：
Liu, Bingfeng;Zhang, Wanying;Zhang, Hui
人类免疫缺陷病毒1型（HIV-1）储存库是潜伏感染细胞的储存库，其中含有具有复制能力的原病毒DNA，这限制了抗逆转录病毒治疗。通过联合抗逆转录病毒治疗（cART）抑制HIV-1可延缓疾病进展，但不能消除病毒库，因此需要终生每天服用抗逆转录病毒药物。为了在无需每日治疗的情况下实现对病毒血症的持久抑制，已经开发了各种策略，包括长效抗逆转录病毒药物（LA-ARVs）、广泛中和抗体（bNAbs）和嵌合抗原受体T （CAR-T）细胞。在这里，我们总结和讨论CAR-T细胞疗法在根除HIV-1储库方面的最新突破。尽管存在巨大的挑战，但CART细胞技术可能成为HIV-1功能性治愈的一种有希望的策略。
Human immunodeficiency virus type 1 (HIV-1) reservoir is a pool of latently infected cells harboring replication-competent proviral DNA that limits antiretroviral therapy. Suppression of HIV-1 by combination antiretroviral therapy (cART) delays progression of the disease but does not eliminate the viral reservoir, necessitating lifetime daily administration of antiretroviral drugs. To achieve durable suppression of viremia without daily therapy, various strategies have been developed, including long-acting antiretroviral drugs (LA-ARVs), broadly neutralizing antibodies (bNAbs), and chimeric antigen receptor T (CAR-T) cells. Here, we summarize and discuss recent breakthroughs in CAR-T cell therapies toward the eradication of HIV-1 reservoir. Although substantial challenges exist, CART cell technology may serve as a promising strategy toward HIV-1 functional cure.